N-aryl pyrrolidine derivatives as beta-secretase inhibitors
    82.
    发明授权
    N-aryl pyrrolidine derivatives as beta-secretase inhibitors 有权
    N-芳基吡咯烷衍生物作为β-分泌酶抑制剂

    公开(公告)号:US07408071B2

    公开(公告)日:2008-08-05

    申请号:US11693034

    申请日:2007-03-29

    CPC分类号: C07D207/16 C07D209/52

    摘要: There is provided a series of substituted N-aryl pyrrolidine derivatives of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R5′, R6, R7, and p as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

    摘要翻译: 提供一系列式(I)的取代的N-芳基吡咯烷衍生物或立体异构体; 或其药学上可接受的盐,其中R 1,R 2,R 3,R 4,R 4, 它们的药物组合物和方法,如本文所定义的,其中R 5,R 5,R 6,R 7, 的使用。 这些化合物通过β-分泌酶抑制淀粉样蛋白前体蛋白(APP)的加工,更具体地抑制Aβ-肽的产生。 本公开涉及可用于治疗与β-淀粉样蛋白产生相关的神经系统疾病的化合物,例如阿尔茨海默病和受抗淀粉样蛋白活性影响的其它病症。

    Substituted Tetrahydroisoquinolines as Beta-secretase Inhibitors
    83.
    发明申请
    Substituted Tetrahydroisoquinolines as Beta-secretase Inhibitors 有权
    取代四氢异喹啉作为β-分泌酶抑制剂

    公开(公告)号:US20080153868A1

    公开(公告)日:2008-06-26

    申请号:US11951516

    申请日:2007-12-06

    CPC分类号: C07K5/06139 C07D471/04

    摘要: There is provided a series of tetrahydroisoquinoline diaminopropane compounds of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R, R8 and R9 are as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

    摘要翻译: 提供一系列式(I)的四氢异喹啉二氨基丙烷化合物或立体异构体; 或其药学上可接受的盐,其中R 8 R 8和R 9如本文所定义,其药物组合物和使用方法。 这些化合物通过β-分泌酶抑制淀粉样蛋白前体蛋白(APP)的加工,更具体地抑制Aβ-肽的产生。 本公开涉及可用于治疗与β-淀粉样蛋白产生相关的神经系统疾病的化合物,例如阿尔茨海默病和受抗淀粉样蛋白活性影响的其它病症。

    Gamma-lactams as beta-secretase inhibitors
    84.
    发明授权
    Gamma-lactams as beta-secretase inhibitors 有权
    γ-内酰胺酶作为β-分泌酶抑制剂

    公开(公告)号:US07388007B2

    公开(公告)日:2008-06-17

    申请号:US11206441

    申请日:2005-08-18

    摘要: There is provided a series of novel substituted gamma-lactams of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R4, R5 and R6 as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

    摘要翻译: 提供一系列式(I)的新型取代的γ-内酰胺或立体异构体; 或其药学上可接受的盐,其中R 1,R 2,R 4,R 5和R 5, 它们的药物组合物和使用方法。 这些新型化合物通过β-分泌酶抑制淀粉样前体蛋白(APP)的加工,更具体地,抑制Aβ-肽的产生。 本公开涉及可用于治疗与β-淀粉样蛋白产生相关的神经系统疾病的化合物,例如阿尔茨海默病和受抗淀粉样蛋白活性影响的其它病症。

    N-Aryl Pyrrolidine Derivatives as Beta-Secretase Inhibitors
    86.
    发明申请
    N-Aryl Pyrrolidine Derivatives as Beta-Secretase Inhibitors 有权
    N-芳基吡咯烷衍生物作为β-分泌酶抑制剂

    公开(公告)号:US20070232679A1

    公开(公告)日:2007-10-04

    申请号:US11693034

    申请日:2007-03-29

    CPC分类号: C07D207/16 C07D209/52

    摘要: There is provided a series of substituted N-aryl pyrrolidine derivatives of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R5′, R6, R7, and p as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

    摘要翻译: 提供一系列式(I)的取代的N-芳基吡咯烷衍生物或立体异构体; 或其药学上可接受的盐,其中R 1,R 2,R 3,R 4,R 4, 它们的药物组合物和方法,如本文所定义的,其中R 5,R 5,R 6,R 7, 的使用。 这些化合物通过β-分泌酶抑制淀粉样蛋白前体蛋白(APP)的加工,更具体地抑制Aβ-肽的产生。 本公开涉及可用于治疗与β-淀粉样蛋白产生相关的神经系统疾病的化合物,例如阿尔茨海默病和受抗淀粉样蛋白活性影响的其它病症。

    Compositions containing sertraline and a 5-HT.sub.1D receptor agonist or
antagonist
    90.
    发明授权
    Compositions containing sertraline and a 5-HT.sub.1D receptor agonist or antagonist 失效
    含有舍曲林和5-HT1D受体激动剂或拮抗剂的组合物

    公开(公告)号:US5597826A

    公开(公告)日:1997-01-28

    申请号:US306230

    申请日:1994-09-14

    CPC分类号: A61K45/06 Y10S514/811

    摘要: The present invention relates to novel compositions containing the serotonin selective re-uptake inhibitor (SSRI), preferably (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine, and an agonist or antagonist of the serotonin 1 (5-HT.sub.1) receptor and to the use of such compositions for treating or preventing a condition selected from mood disorders, including depression, seasonal affective disorders and dysthmia, anxiety disorders including generalized anxiety disorder and panic disorder; agoraphobia, avoidant personality disorder; social phobia; obsessive compulsive disorder; post-traumatic stress disorder; memory disorders including dementia, amnestic disorders and age-associated memory impairment; disorders of eating behavior, including anorexia nervosa and bulimia nervosa; obesity; cluster headache; migraine; pain; Alzheimer's disease; chronic paroxysmal hemicrania; headache associated with vascular disorders; Parkinson's disease, including dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias; endocrine disorders such as hyperprolactinaemia; vasospasm (particularly in the cerebral vasculature); hypertension; disorders in the gastrointestinal tract where changes in motility and secretion are involved; sexual dysfunction, including premature ejaculation; and chemical dependencies.

    摘要翻译: 本发明涉及含有5-羟色胺选择性再摄取抑制剂(SSRI),优选(1S-顺式)-4-(3,4-二氯苯基)-1,2,3,4-四氢-N-甲基 - 以及5-羟色胺1(5-HT1)受体的激动剂或拮抗剂,以及这些组合物用于治疗或预防选自情绪障碍,包括抑郁症,季节性情感障碍和心律不适的病症的用途,焦虑症包括广泛性 焦虑症和恐慌症; 广场恐惧症,避孕人格障碍; 社交恐惧症 强迫症 创伤后应激障碍; 记忆障碍包括痴呆,遗忘性障碍和年龄相关记忆障碍; 饮食行为障碍,包括神经性厌食症和神经性贪食症; 肥胖; 簇头痛; 偏头痛 疼痛; 阿尔茨海默氏病; 慢性阵发性黑血病 与血管疾病相关的头痛; 帕金森病,包括帕金森病中的痴呆,精神安定药物引起的帕金森综合征和迟发性运动障碍; 内分泌紊乱如高泌乳素血症; 血管痉挛(特别是脑血管系统); 高血压; 涉及运动和分泌变化的胃肠道疾病; 性功能障碍,包括早泄; 和化学依赖性。